Abstract L-Sox5 is a member of sex-determining region Y-type high mobility group box (SOX) family of transcription factors. We assessed the effects of retroviral overexpression of L-Sox5 on chondrocyte differentiation using the clonal murine cell line ATDC5. We observed a temporal-restricted expression pattern of L-Sox5 in insulininduced ATDC5 cells differentiating toward chondrocyte lineage. The protein expression levels of L-Sox5 showed a drastic decrease in contrast to unaltered mRNA levels during differentiation. L-Sox5 delayed the differentiation of ATDC5 cells as evidenced by Alcian blue staining for proteoglycan synthesis. The mRNA levels of chondrocyte and hypertrophic/osteoarthritic markers were markedly decreased or delayed in L-Sox5 overexpressing cells. L-Sox5 abrogated the promoter activity of Runx2. These results suggest that L-Sox5 protein expression may diminish along with the progress of chondrogenic differentiation. L-Sox5 may act as a negative regulator if expressed aberrantly at least in part by regulating the critical fate of chondrogenesis.
Introduction
Endochondral ossification is a complex and multistep process involving gradual replacement of embryonic cartilaginous model by bone. Mesenchymal precursor cells condense to form an anlage for the endochondral skeleton. The condensed cells initiate as proliferating chondrocytes, become prehypertrophic chondrocytes and end as hypertrophic chondrocytes [1] . Proliferating chondrocytes secrete extracellular matrix (ECM) proteins such as type II Collagen and Aggrecan; chondrocytes then exit the cell cycle, turn prehypertrophic, and synthesize type X collagen [1] . As hypertrophic chondrocytes become apoptotic, blood vessels invade the cartilaginous template that is eventually replaced by bone.
The sex-determining region Y-type high mobility group box (Sox) family transcription factors, L-Sox5, Sox6, and Sox9 (Sox trio), have been reported to tightly regulate chondrocyte differentiation and cartilage development [2] . Sox9 is the master transcription factor for chondrocyte lineage commitment and differentiation. Campomelic dysplasia in humans occurs due to heterozygous mutations in the gene whereas its knock out in mice results in complete absence of chondrocyte and bone [3] . L-Sox5 (a longer isoform of Sox5) and Sox6 are the two other members of the Sox family and function as co-activators of Sox9 during chondrogenesis [4] . L-Sox5 and Sox6 have essential but redundant roles in cartilage development [2] . Even though combination of L-Sox5, Sox6, and Sox9 have been shown to be sufficient to induce and maintain overt chondrogenesis in cultured cells, growing body of evidence suggests that they inhibit the terminal differentiation stage of chondrocytes [5] . Nevertheless, the precise mode of action of the Sox trio is not completely understood till date due to the fact that they are involved in successive multiple steps of the complex chondrocyte differentiation pathway. Since, the Sox genes are essential for cartilage development, understanding the role of L-Sox5 would provide novel insights for advancing cartilage biology.
ATDC5 is a mouse embryonal carcinoma-derived cell line that mimics the chondrocyte differentiation processes from chondroprogenitors to fully differentiated and hypertrophic chondrocytes in a sequential, temporally regulated manner [6] . These cells are less phenotypically diverse than primary cultures and therefore widely used as a model to study in vitro chondrogenesis [7] . Upon stimulation with insulin ATDC5 cells form nodule-like aggregates and express chondrogenic markers (type II Collagen and sulfated Glycosaminoglycans) and further differentiate to become hypertrophic and express type X collagen [7] . The sequential changes that occur during early and late chondrogenesis are critical for the fate of different chondrocytes. Since L-Sox5 is a major Sox family member, we assessed its role in chondrocyte differentiation. We demonstrate that overexpression of L-Sox5 in ATDC5 cells delays fully chondrogenic differentiation and correlates with reduced expression of chondrogenic and hypertrophic/ osteoarthritic markers.
Materials and methods

Reagents and antibodies
Insulin (#I0516), human transferrin (#T3309), sodium selenite (#S5261), ascorbate 2-phosphate (#A8960), anti-FLAG antibodies (#F1804), blasticidine (#15205), puromycin (#P8833), and Alcian blue 8GX (#A3157) were all purchased from Sigma. G418 (#345810) was bought from Merck.
Cell culture
The mouse chondroprogenitor cell line ATDC5 was maintained in DMEM/F12 (1:1) (GIBCO) containing 5 % fetal bovine serum (FBS; Hyclone), 10 lg ml -1 human transferrin, 30 nM sodium selenite, 37.5 lg ml -1 ascorbate 2-phosphate, 100 U ml -1 penicillin, and 100 U ml
streptomycin. For chondrocyte differentiation, cells (5 9 10 4 /well) were seeded and cultured to reach 100 % confluency (this time point was regarded as day 0 for subsequent differentiation), then medium was supplemented with 10 lg ml -1 insulin and cells were cultured for up to 14 days. PLAT-E packaging cell lines were maintained in DMEM containing 10 % FBS, 1 lg ml -1 puromycin, 10 lg ml -1 blasticidine, 100 U ml -1 penicillin, and 100 U ml -1 streptomycin in 6-well plates coated with rat tail type I Collagen (Upstate).
Plasmid construction
The plasmid vector pcDNA 5 0 UT-FLAG and cDNA clone for L-Sox5 in the same vector were kindly provided by Dr. Lefebvre [4] . For constructing the control pMXs retroviral vector, a blunt HindIII-XbaI fragment containing the FLAG tag from pcDNA 5 0 UT-FLAG was introduced into the blunt EcoRI ends of pMXs/neo. This empty construct was used to generate the control cell line in this study. To introduce the FLAG-tagged L-Sox5 into the pMXs retroviral vector, the blunt HindIII-XbaI fragment containing L-Sox5 was ligated to the blunt EcoRI ends of pMXs/neo. All the constructs were confirmed by restriction enzymatic mapping.
Generation of the ATDC5 cell lines overexpressing L-Sox5 and their mock control
To generate the ATDC5 stable cell lines for this study, we used a retroviral system. PLAT-E cells were transfected with the pMXs constructs using Fugene-6 transfection reagent (Roche) according to the manufacturer's instructions. After 72 h, medium was collected as virus-containing supernatant. Then the virus supernatant was filtered through a 0.45-lm filter (Millipore) and was mixed in 1000:1 with polybrene from a stock solution of 5 mg ml -1 (Sigma). ATDC5 cells were seeded 1 day before infection and were transduced with the polybrene virus supernatant for 6 h followed by replacement with fresh medium. Twenty-four hours later, ATDC5 cells were subjected to selection under 400 lg ml -1 G418. The stable cell lines were confirmed by Western blot using anti-FLAG antibodies.
RNA preparation and RT-PCR assay
Total RNA was extracted from cells with Trizol reagent (Invitrogen). Reverse transcription and PCR were performed using Improm-II reverse transcriptase (Promega) and Taq polymerase premix (Takara), as per manufacturer's instructions. The primers are shown in supplementary Table 1 . PCR reaction was performed on a P92 Thermal Cycler (Thermal Electron Corporation).
Alcian blue staining
To analyze differentiation, cells were washed with PBS twice, fixed with 10 % (v/v) formaldehyde in PBS at room temperature for 20 min, and stained with 0.1 % Alcian blue 8GX in 0.1 N HCL overnight. The next day, cells were rinsed with distilled water and examined under a microscope.
Western blot
Cells were lysed in RIPA buffer supplemented with protease inhibitors. 30 lg of proteins was loaded into each lane and was separated by SDS-PAGE and subsequently transferred to a PVDF membrane. Membranes were blocked in 5 % nonfat milk to prevent non-specific binding followed by incubation with the respective primary antibodies. Results were visualized using the ECL Plus detection kit (GE Healthcare) according to the manufacturer's instructions.
Microarray analysis
A detailed description is provided in supplementary information.
Transient transfection and dual luciferase assay
The RUNX2 promoter and 5 0 -UTR region (-2859 to ?395), as illustrated in the sequence with genbank number AY090738, were amplified using high-fidelity polymerase and cloned into pREP4-Luc. 293T cells grown in 6-well plates were transfected by Fugene 6 transfection reagent with 0.5 lg of the RUNX2 promoter-luciferase construct along with 0.5 lg of the L-Sox5 expression construct or its empty vector [4] . Cells in each well were also cotransfected with 0.1 lg of pREP7-RLuc plasmids as an internal control. Relative luciferase activities were measured 40 h after transfection by the dual luciferase assay system (Promega) on a TD-20/20 luminometer (Turner Designs). For characterizing Sox6 and Sox9, the same methodology was employed as mentioned above for L-Sox5 assays. For L-Sox5 and Sox6 or L-Sox5 and Sox9 analysis, a total of 0.5 lg of respective plasmids (0.25 lg L-Sox5 and 0.25 lg Sox6 or Sox9) were cotransfected into the cells.
Results
Overexpression of L-Sox5 inhibited in vitro chondrogenesis
To delineate the function of L-Sox5 protein in chondrocyte differentiation, we established ATDC5 variant cell lines overexpressing L-Sox5 and their mock controls. The protein levels of L-Sox5 weakened after induction of chondrocyte differentiation (Fig. 1a) ; however, mRNA expression levels of L-Sox5 did remained unaltered throughout chondrocyte differentiation (Fig. 1b) .
Furthermore, to examine the chondrogenic ability of the cell lines overexpressing L-Sox5 and their mock controls, Alcian blue staining for proteoglycan biosynthesis was performed. Alcian blue-positive cartilaginous nodules were detected for the control cells as earlier as day 7, and overt cartilaginous nodules were detected at day 14 (Fig. 1c) . Intriguingly, even though L-Sox5 overexpression did not abolish the commitment to chondrocyte lineage, no Alcian blue-positive nodules were detected at day 7, and weaker Alcian blue-positive nodules were detected at day 14, for the L-Sox5 overexpressing cells (Fig. 1c) .
L-Sox5 suppressed cartilage-specific markers gene expression, hypertrophic markers gene expression, and osteoarthritis-associated ECM protein's gene expression RT-PCR assay was conducted to examine gene expression of the cartilage-specific matrix proteins during chondrocyte differentiation. As shown in Fig. 2a , L-Sox5 (Fig. 2b, c) . We then performed microarray to investigate genes that were regulated by overexpression of L-Sox5 in ATDC5 cells (supplementary Table 2 ). Indeed, we also found that gene expression of Decorin and Lumican was identified to be decreased (top 10th and 15th, respectively, among the downregulated 395 genes shown in supplementary Table 2 ) by L-Sox5 overexpression. Concomitantly, microarray data confirmed that Asporin gene expression was dramatically decreased by L-Sox5 overexpression (top 8th among the downregulated 395 genes shown in supplementary Table 2 ).
L-Sox5 suppresses Runx2 promoter activity
To characterize the effects of L-Sox5 on chondrocyte hypertrophy, we performed dual luciferase assay. We found that L-Sox5 significantly inhibited the RUNX2 promoter activity (Fig. 3a) . To exactly delineate if Sox6 could also have a suppressive effect on Runx2 promoter activity, Sox6 plasmid either alone or in combination with L-Sox5 was cotransfected and assessed for promoter activity. Sox6-mediated repression of Runx2 promoter activity was similar to Sox5 repression as well as cotransfection of these plasmids did not display a suppressive effect greater than the plasmids when transfected alone (Fig. 3b) . To find out whether L-Sox5 activity is dependent or independent of Sox9, another reporter assay was conducted. As seen in Fig. 3c , L-Sox5 alone drastically downregulated the Runx2 promoter activity whereas Sox9 upregulated it. Cotransfection of L-Sox5 and Sox9 led to a decrease in Runx2 promoter activity.
Discussion
In the present study, we investigated the role of L-Sox5 during chondrocyte differentiation by retrovirally overexpressing the gene in ATDC5 cells. We found inhibitory effects of L-Sox5 on the differentiation of ATDC5 chondroprogenitor cells.
ATDC5, a teratocarcinoma-derived cell line serves as an excellent model for studying molecular mechanisms regulating the two crucial stages of cartilage formation: early differentiation of committed stem cells and the terminal differentiation of proliferating to hypertrophic chondrocytes [8] . In this study, we analyzed the effects of L-Sox5 on chondrogenesis that involves the differentiation of committed stem cell to proliferating chondrocytes and late chondrogenesis that entails fully differentiation of proliferating chondrocytes. Although chondrogenesis occurs in a sequential and stage-specific manner, it is not clear how L-Sox5 controls the balance between early and late chondrogenesis. Here, we first demonstrated that L-Sox5 protein levels diminish along with chondrocyte differentiation whereas mRNA levels remain unaffected. None of the previous studies has reported this phenomenon although unaltered gene expression of L-Sox5 during in vitro chondrogenesis has been observed earlier in human bone marrow stem cell chondrogenic cultures [9] . Henceforth, we found a critical event regulating cartilage formation where protein expression of L-Sox5 is reduced to allow chondrogenesis with mRNA levels staying unaffected.
Sox protein expression levels have been reported to be regulated by the ubiquitin-proteasome pathway. Sox9 has been shown to be degraded by the 26S proteasome and is a specific target for the E6-AP ubiquitin ligase [10] . An E3 ligase Trip12, a HECT domain E3 ubiquitin ligase, recognizes and polyubiquitinates Sox6 [11] . Therefore, these lines of evidence indicate the possibility that L-Sox5 protein might undergo proteasome-mediated degradation to maintain the differentiation of cells toward chondrogenic lineage. Further studies that assess whether L-Sox5 protein downregulation occurs at protein synthesis or proteasomemediated degradation level would be interesting.
During initiation of chondrogenesis, mesenchymal stem cells condense and form cartilaginous nodules, a prerequisite for cartilage formation [12] . Under influence of insulin ATDC5 cells lose contact inhibition and grow beyond confluence to produce multiple layers of cells for forming cartilaginous nodules [13] . We found that L-Sox5 delayed the differentiation of insulin-induced ATDC5 cells by attenuating the cartilage nodule formation as assessed by alcian blue staining. Furthermore, L-Sox5 inhibited the chondrocyte markers gene expression for type II Collagen, Aggrecan, Comp, Lumican, Decorin, Matrilin, and suppressed hypertrophic/osteoarthritic markers gene expression for Runx2, type X collagen, and Asporin. In line with this Decorin, Lumican, and Asporin was found to be downregulated by L-Sox5 in microarray results. Expression of Asporin is associated with osteoarthritis and that of the other extracellular proteins i.e., Osteoglycin, Osteomodulin, Periostin, and Bone Sialoprotein, that are found to be downregulated by L-Sox5 in this study might also be associated with osteoarthritis [12, 14] . Nonetheless, how these genes are regulated in the pathophysiological context of cartilage is largely unknown. Possible explanation might be that Runx2 expression and function are completely inhibited by PTHrP and is silent in chondrocytes before prehypertrophy and hypertrophy [15] . These results indicate that constitutive overexpression of L-Sox5 possibly leads to negative regulation at least in part by regulating critical fate of chondrogenesis.
It has been reported that L-Sox5 and Sox6 are functionally redundant in chondrogenesis and cartilage development [16] . Dual luciferase assay results obtained in this study clearly showed that L-Sox5 and Sox6 suppressed Runx2 promoter activity almost at same levels, further corroborating with the results from Smits et al. [16] . Furthermore, our promoter assay results demonstrated that although Sox9 alone did upregulate Runx2 promoter activity, cotransfection with L-Sox5 potently repressed Sox-9 mediated upregulation. Therefore, these results suggest that L-Sox5 function on the RUNX2 promoter might be independent of Sox9.
Our results provide first line of evidence that overexpression of L-Sox5 in ATDC5 cells reduces the chondrogenic differentiation without abolishing the commitment of cells toward chondrogenic lineage. These results indicate that L-Sox5 in ATDC5 cells might play an inhibitory role during chondrocyte maturation. This inhibitory role is mainly manifested by our observation of delayed or suppressed expression of chondrocyte marker genes. Even though similar and dissimilar regulatory mechanisms have been uncovered [3, 17, 18] , it is still difficult for us to explain the inhibitory role by L-Sox5 found in this study, so more efforts are needed to uncover the mechanisms underlying cartilage-specific gene expression using our in vitro model.
In conclusion, results from our gain of function study suggest that L-Sox5 is an important regulator of chondrogenesis where it delays fully differentiation. Understanding of molecular regulatory network of L-Sox5 may prove useful in advancing cartilage tissue engineering and the data generated in this study shall aid in designing further studies to find novel genes regulated by L-Sox5 and the underlying mechanisms.
